Department of Cardio-pulmonary Functions, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and therapy, Tianjin Medical University, Tianjin, China.
Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and therapy, Tianjin Medical University, Tianjin, China.
Clin Chim Acta. 2018 Sep;484:272-277. doi: 10.1016/j.cca.2018.05.059. Epub 2018 May 31.
A novel systemic immune-inflammation index (SII) has been recently reported to be associated with clinical outcome in several tumors. However, the prognostic value of SII has not been reported in operable non-small cell lung carcinoma (NSCLC). We aimed to investigate its clinical and prognostic value in patients with operable NSCLC underwent curative surgery.
Four hundred ten NSCLC patients staged I-IIIA were included in this retrospective study. The SII was calculated by the formula: neutrophil× platelet/lymphocyte. Receiver operating characteristic (ROC) curve was used to determine the optimal cut-off value for SII. Kaplan-Meier method and Cox proportional regression were used to analyze the prognostic value of SII.
Patients were stratified into high low SII (≤395.4) and SII (>395.4) groups. High SII was significantly associated with advanced T stage and positive lymph node metastasis. Kaplan-Meier survival analysis showed that SII, PLR, NLR and LMR were all associated with OS. Multivariate analysis identified that SII was an independent predictor of OS. Furthermore, SII remained prognostic significance for NSCLC patients stratified by TNM subgroups.
Preoperative SII was a powerful prognostic biomarker for predicting outcome in patients with operable NSCLC. Preoperative SII may assist clinicians treatment strategy making and individual treatment choice.
最近有报道称，一种新型的全身免疫炎症指数（SII）与多种肿瘤的临床预后相关。然而，SII 在可手术的非小细胞肺癌（NSCLC）中的预后价值尚未见报道。我们旨在研究其在接受根治性手术的可手术 NSCLC 患者中的临床和预后价值。
本回顾性研究纳入了 410 例分期为 I-IIIA 的 NSCLC 患者。SII 通过公式：中性粒细胞×血小板/淋巴细胞计算得出。采用受试者工作特征（ROC）曲线确定 SII 的最佳截断值。Kaplan-Meier 法和 Cox 比例回归分析 SII 的预后价值。
患者被分为高 SII（≤395.4）和低 SII（>395.4）组。高 SII 与较晚的 T 分期和阳性淋巴结转移显著相关。Kaplan-Meier 生存分析表明，SII、PLR、NLR 和 LMR 均与 OS 相关。多因素分析表明，SII 是 OS 的独立预测因子。此外，SII 对 TNM 亚组分层的 NSCLC 患者仍具有预后意义。
术前 SII 是预测可手术 NSCLC 患者预后的有力预后生物标志物。术前 SII 可能有助于临床医生制定治疗策略和选择个体化治疗。
